Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxonidine in diabetic nephropathy
NCT01094769Phase 4Completed
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- Apr 2011
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in diabetic nephropathy (DN) comparing Moxonidine with Placebo (2 arms). Primary endpoint: Urine albumin/creatinine ratio at 12 weeks. Started Apr 2011; status: completed.
02
Drugs
moxonidine
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01094769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01094769.